Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
New Advances in Myasthenia Gravis
share announcement

New Advances in Myasthenia Gravis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 29 May 2025 | Viewed by 1047

Special Issue Editor

Dr. Shingo Konno

E-Mail Website
Guest Editor
Department of Neurology, Toho University Ohashi Medical Center, 2-22-36 Ohashi, Meguro-ku, Tokyo 153-8515, Japan
Interests: myasthenia gravis; autoimmune neurology; neuroimmunology; neuroregeneration

Special Issue Information

Dear Colleagues,

Myasthenia gravis (MG) is a chronic autoimmune disorder that affects neuromuscular transmission, leading to muscle weakness and fatigue. Recent advancements in immunotherapy, biological markers, and neuroregenerative strategies offer new hope for improving the diagnosis and management of MG. This Special Issue, titled ‘New Advances in Myasthenia Gravis’, aims to collect cutting-edge research that explores innovative treatment modalities, underlying mechanisms, and long-term management strategies for MG patients.

We encourage contributions from a wide range of studies, including clinical trials, translational research, drug repurposing, and basic science that highlight the impact of novel therapeutic interventions and patient care models. The issue seeks to provide a comprehensive overview of the latest scientific discoveries and their implications for future research and clinical practice in neuromuscular disorders.

We look forward to your valuable submissions, which will further our understanding of myasthenia gravis and promote better outcomes for patients.

Dr. Shingo Konno
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • myasthenia gravis
  • clinical trials
  • translational research
  • drug repurposing
  • biological markers
  • experimental autoimmune myasthenia gravis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 479 KiB  
Article
Functional Status Enhances the FRAX® Prediction of Fractures in Myasthenia Gravis: A 10-Year Cohort Study
by Shingo Konno, Takafumi Uchi, Hideo Kihara and Hideki Sugimoto
J. Clin. Med. 2025, 14(9), 3260; https://doi.org/10.3390/jcm14093260 - 7 May 2025
Viewed by 148
Abstract
Background: Patients with myasthenia gravis (MG) are susceptible to fractures due to glucocorticoid (GC) use and disease-related functional impairment affecting activities of daily living (ADL). The Fracture Risk Assessment Tool (FRAX®) estimates fracture probability but does not incorporate disease-specific functional [...] Read more.
Background: Patients with myasthenia gravis (MG) are susceptible to fractures due to glucocorticoid (GC) use and disease-related functional impairment affecting activities of daily living (ADL). The Fracture Risk Assessment Tool (FRAX®) estimates fracture probability but does not incorporate disease-specific functional status. We investigated whether combining FRAX® with the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale improves fracture risk stratification in MG patients. Methods: This single-center prospective cohort study followed 53 MG patients for 10 years (2012–2022) at Toho University Ohashi Medical Center, Japan. Patients were categorized into four groups based on baseline FRAX® probability (calculated with bone mineral density [BMD]) and MG-ADL scores using median splits: high FRAX®/high MG-ADL (HH), high FRAX®/low MG-ADL (HL), low FRAX®/high MG-ADL (LH), and low FRAX®/low MG-ADL (LL). The primary outcome was incident major osteoporotic fracture (MOF). Results: Over 10 years, nine MOFs occurred: seven in the HH group (43.8%), two in the HL group (16.7%), and none in the LH or LL groups. Fracture-free survival differed significantly among the groups (log-rank p < 0.001), with the HH group exhibiting the lowest survival rate. Baseline characteristics, including age, disease duration, MG severity scores, BMD, and FRAX® scores, differed significantly among groups. Specific MG-ADL items reflecting greater impairment (impairment of ability to arise from a chair, double vision, and ptosis) were significantly more pronounced in the HH group at baseline. Conclusions: Combining baseline FRAX® scores with the MG-ADL assessment effectively stratifies long-term MOF risk in patients with MG. Individuals with both high FRAX® and high MG-ADL represent a particularly high-risk subgroup. This dual-assessment approach may improve the identification of patients requiring targeted preventive interventions. Full article
(This article belongs to the Special Issue New Advances in Myasthenia Gravis)
►▼ Show Figures

Figure 1

13 pages, 234 KiB  
Article
Prevalence of Elevated CK Levels, Myositis-Specific and Myositis-Associated Antibodies, Myositis, and Other Neuromuscular Diseases in Myasthenia Gravis Patients—Experience from an Eastern European Tertiary Center
by Márk Kozák, Edina Kovács, Melinda Nagy-Vince, Attila Tóth and Judit Boczán
J. Clin. Med. 2025, 14(7), 2449; https://doi.org/10.3390/jcm14072449 - 3 Apr 2025
Viewed by 537
Abstract
Background: Myasthenia gravis (MG) and idiopathic inflammatory myopathy (IIM) are autoimmune diseases that affect the musculoskeletal system. The association of the two diseases is rare. Their management is different, so it is important to recognize the concomitant presentation. Methods: In this cross-sectional study, [...] Read more.
Background: Myasthenia gravis (MG) and idiopathic inflammatory myopathy (IIM) are autoimmune diseases that affect the musculoskeletal system. The association of the two diseases is rare. Their management is different, so it is important to recognize the concomitant presentation. Methods: In this cross-sectional study, we study the presence of CK elevation, myositis-specific and myositis-associated antibodies (MSA/MAA), and vitamin D levels in a cohort of 101 MG patients. Electromyography, limb magnetic resonance imaging (MRI), and, in some cases, muscle biopsy were performed when IIM was suspected. We reviewed the patients’ medical records to access the results of these tests if they had been performed previously. Results: CK elevation was detected in 10 patients (9.9%). We identified one case of anti-Jo-1 antibody-positive polymyositis and two cases of possible myositis. MSA/MAA antibodies were not found in the patients with high CK levels, except for the one with anti-Jo-1-positive IIM. One patient with elevated CK levels had an overlapping muscular dystrophy. MSA/MAA antibodies were detected in 19 patients (18.8%). A total of 37% had high-titer antibodies and concomitant systemic autoimmune diseases, while 63% had low-titer antibodies, most of whom had no systemic autoimmune disease. Low serum vitamin D levels were found in 67.3% of patients. Comparison of myasthenia gravis composite (MGC) scores between patients with low and normal vitamin D levels did not show a statistically significant difference. Conclusions: Our results may raise awareness among neuromuscular specialists caring for MG patients of the possibility of associated myositis or other neuromuscular diseases and the need to assess vitamin D levels. Although deficiency was frequent, its impact on MG severity remains unclear, necessitating further investigation into its immunological relevance. Full article
(This article belongs to the Special Issue New Advances in Myasthenia Gravis)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop